Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Bryan R Haugen

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-3921

    Collapse Research 
    Collapse research activities and funding
    R01CA233546     (HAUGEN, BRYAN R.)Apr 1, 2019 - Mar 31, 2025
    NIH
    Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer
    Role: Principal Investigator
    R01CA175994     (HAUGEN, BRYAN R.)Apr 1, 2013 - Mar 31, 2019
    NIH
    TXNIP as a Key Regulator of Thyroid Cancer Metabolism and Aggressiveness
    Role: Principal Investigator
    R01CA155512     (HAUGEN, BRYAN R.)Aug 3, 2011 - Jun 30, 2017
    NIH
    The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer
    Role: Principal Investigator
    RC1CA147371     (HAUGEN, BRYAN R.)Sep 30, 2009 - Aug 31, 2012
    NIH
    A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery
    Role: Co-Principal Investigator
    R01CA100560     (HAUGEN, BRYAN R)Mar 1, 2005 - Jul 31, 2012
    NIH
    Thiazolidinediones as Thyroid Cancer Therapy
    Role: Principal Investigator
    R01DK054383     (HAUGEN, BRYAN R)Aug 15, 2000 - Jul 31, 2006
    NIH
    ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION
    Role: Principal Investigator
    K08DK002331     (HAUGEN, BRYAN R)Jan 1, 1995 - Dec 31, 2000
    NIH
    PIT-1T AND THYROTROPIN BETA SUBUNIT GENE EXPRESSION
    Role: Principal Investigator
    F32DK008796     (HAUGEN, BRYAN R)Jan 10, 1993
    NIH
    ISOLATION AND STUDY OF TSHB GENE TRANSCRIPTION FACTORS
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, Shonka DC, Singer MC, Stack BC, Wirth LJ, Wong RJ, Randolph GW. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. JAMA Otolaryngol Head Neck Surg. 2024 03 01; 150(3):265-272. PMID: 38206595.
      View in: PubMed
    2. Pozdeyev N, Dighe M, Barrio M, Raeburn C, Smith H, Fisher M, Chavan S, Rafaels N, Shortt JA, Lin M, Leu MG, Clark T, Marshall C, Haugen BR, Subramanian D, Crooks K, Gignoux C, Cohen T. Thyroid Cancer Polygenic Risk Score Improves Classification of Thyroid Nodules as Benign or Malignant. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):402-412. PMID: 37683082.
      View in: PubMed
    3. Chiosea S, Hodak SP, Yip L, Abraham D, Baldwin C, Baloch Z, Gulec SA, Hannoush ZC, Haugen BR, Joseph L, Kargi AY, Khanafshar E, Livhits MJ, McIver B, Patel K, Patel SG, Randolph GW, Shaha AR, Sharma J, Stathatos N, van Zante A, Carty SE, Nikiforov YE, Nikiforova MN. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management. J Clin Endocrinol Metab. 2023 10 18; 108(11):2999-3008. PMID: 37071871.
      View in: PubMed
    4. Wahdan-Alaswad RS, Edgerton SM, Kim HM, Tan AC, Haugen BR, Liu B, Thor AD. Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer. Cell Cycle. 2023 Sep 18; 1-20. PMID: 37723865.
      View in: PubMed
    5. Greca A, Grau L, Arbet J, Liao LM, Sosa JA, Haugen BR, Kitahara CM. Anthropometric, dietary, and lifestyle factors and risk of advanced thyroid cancer: The NIH-AARP diet and health cohort study. Clin Endocrinol (Oxf). 2023 12; 99(6):586-597. PMID: 37694684.
      View in: PubMed
    6. Barrio M, Raeburn CD, McIntyre R, Albuja-Cruz M, Haugen BR, Pozdeyev N. Computer-Assisted Levothyroxine Dose Selection for the Treatment of Postoperative Hypothyroidism. Thyroid. 2023 05; 33(5):547-555. PMID: 37084246.
      View in: PubMed
    7. Jeon MJ, Haugen BR. Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models. Endocrinol Metab (Seoul). 2022 12; 37(6):830-838. PMID: 36604954.
      View in: PubMed
    8. Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022 02; 32(2):153-163. PMID: 34641722.
      View in: PubMed
    9. Mehta V, Naraparaju A, Liao D, Davies L, Haugen BR, Kopp PA, Mandel SJ, Nikiforov YE, Ross DS, Shin JJ, Tuttle RM, Randolph GW. What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision. Thyroid. 2022 04; 32(4):421-428. PMID: 34915744.
      View in: PubMed
    10. Mayson SE, Chan CM, Haugen BR. Tailoring the approach to radioactive iodine treatment in thyroid cancer. Endocr Relat Cancer. 2021 09 03; 28(10):T125-T140. PMID: 34254949.
      View in: PubMed
    11. Figge JJ, Gooding WE, Steward DL, Yip L, Sippel RS, Yang SP, Scheri RP, Sipos JA, Mandel SJ, Mayson SE, Burman KD, Folek JM, Haugen BR, Sosa JA, Parameswaran R, Tan WB, Nikiforov YE, Carty SE. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology? Thyroid. 2021 11; 31(11):1673-1682. PMID: 34340592.
      View in: PubMed
    12. Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 01 15; 27(2):585-597. PMID: 33097494.
      View in: PubMed
    13. Sawka AM, Alexander EK, Bianco AC, Chou R, Haugen BR, Kopp PA, Pearce EN, Ross DS, Smallridge RC, Jonklaas J. Challenges in Developing Recommendations Based on Low-Quality Evidence in Thyroid Guidelines. Thyroid. 2021 01; 31(1):3-7. PMID: 32900277.
      View in: PubMed
    14. Pozdeyev N, Erickson TA, Zhang L, Ellison K, Rivard CJ, Sams S, Hirsch FR, Haugen BR, French JD. Comprehensive Immune Profiling of Medullary Thyroid Cancer. Thyroid. 2020 09; 30(9):1263-1279. PMID: 32242507.
      View in: PubMed
    15. Sawka AM, Gagliardi AR, Haymart MR, Sturgeon C, Bernet V, Hoff K, Angelos P, Brito JP, Haugen BR, Kim B, Kopp PA, Mandel SJ, Ross DS, Samuels M, Sarne D, Sinclair C, Jonklaas J. A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines. Thyroid. 2020 01; 30(1):25-33. PMID: 31830853.
      View in: PubMed
    16. Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res. 2019 11 15; 25(22):6883-6884. PMID: 31732665.
      View in: PubMed
    17. Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 05 15; 25(10):3141-3151. PMID: 30737244.
      View in: PubMed
    18. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048. PMID: 30733375.
      View in: PubMed
    19. Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2019 02 01; 5(2):204-212. PMID: 30419129.
      View in: PubMed
    20. Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck. 2019 04; 41(4):843-856. PMID: 30561068.
      View in: PubMed
    21. Mayson SE, Haugen BR. Molecular Diagnostic Evaluation of Thyroid Nodules. Endocrinol Metab Clin North Am. 2019 03; 48(1):85-97. PMID: 30717912.
      View in: PubMed
    22. McIver B, Freeman J, Shah JP, Shaha AR, Haugen B, Cohen E, Witterick IJ, Randolph GW. Summary of the Third World Congress on Thyroid Cancer. Thyroid. 2018 11; 28(11):1401-1405. PMID: 30303467.
      View in: PubMed
    23. Deaver KE, Haugen BR, Pozdeyev N, Marshall CB. Outcomes of Bethesda categories III and IV thyroid nodules over 5?years and performance of the Afirma gene expression classifier: A single-institution study. Clin Endocrinol (Oxf). 2018 Aug; 89(2):226-232. PMID: 29791966.
      View in: PubMed
    24. Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 06; 28(6):739-747. PMID: 29774792.
      View in: PubMed
    25. Sawka AM, Carty SE, Haugen BR, Hennessey JV, Kopp PA, Pearce EN, Sosa JA, Tufano RP, Jonklaas J. American Thyroid Association Guidelines and Statements: Past, Present, and Future. Thyroid. 2018 06; 28(6):692-706. PMID: 29698130.
      View in: PubMed
    26. Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 07 01; 24(13):3059-3068. PMID: 29615459.
      View in: PubMed
    27. Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 04 01; 103(4):1277-1281. PMID: 29373711.
      View in: PubMed
    28. Patel NU, Lind KE, McKinney K, Clark TJ, Pokharel SS, Meier JM, Stamm ER, Garg K, Haugen B. Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer. AJNR Am J Neuroradiol. 2018 Apr; 39(4):756-761. PMID: 29449283.
      View in: PubMed
    29. French JD, Haugen BR. Thyroid cancer: CAR T cell therapy - potential in advanced thyroid cancer? Nat Rev Endocrinol. 2018 01; 14(1):10-11. PMID: 29170541.
      View in: PubMed
    30. French JD, Haugen BR. Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies? J Clin Endocrinol Metab. 2017 07 01; 102(7):2131-2132. PMID: 28899074.
      View in: PubMed
    31. Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid. 2017 06; 27(6):751-756. PMID: 28463585.
      View in: PubMed
    32. Shrestha RT, Malabanan A, Haugen BR, Levy EG, Hennessey JV. ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT. Endocr Pract. 2017 May; 23(5):566-575. PMID: 28225316.
      View in: PubMed
    33. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 04; 27(4):481-483. PMID: 28114862.
      View in: PubMed
    34. French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017 06; 5(6):469-481. PMID: 27773653.
      View in: PubMed
    35. Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017 02 01; 123(3):372-381. PMID: 27741354.
      View in: PubMed
    36. Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. 2016 Aug 09; 7(32):51619-51625. PMID: 27322211.
      View in: PubMed
    37. Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC, Haugen BR, French JD. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2016 07; 101(7):2863-73. PMID: 27045886.
      View in: PubMed
    38. Sinclair CF, Bumpous JM, Haugen BR, Chala A, Meltzer D, Miller BS, Tolley NS, Shin JJ, Woodson G, Randolph GW. Laryngeal examination in thyroid and parathyroid surgery: An American Head and Neck Society consensus statement: AHNS Consensus Statement. Head Neck. 2016 06; 38(6):811-9. PMID: 26970554.
      View in: PubMed
    39. Haugen B. Editorial: Centennial Celebration: An Interview with Dr Bryan Haugen on 100 Years of Thyroid Research. Mol Endocrinol. 2016 Jan; 30(1):1-2. PMID: 26720254.
      View in: PubMed
    40. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26(1):1-133. PMID: 26462967.
      View in: PubMed
    41. Albuja-Cruz MB, Pozdeyev N, Robbins S, Chandramouli R, Raeburn CD, Klopper J, Haugen BR, McIntyre R. A "safe and effective" protocol for management of post-thyroidectomy hypocalcemia. Am J Surg. 2015 Dec; 210(6):1162-8; discussion 1168-9. PMID: 26601651.
      View in: PubMed
    42. Patel NU, McKinney K, Kreidler SM, Bieker TM, Russ P, Roberts K, Glueck DH, Albuja-Cruz M, Klopper J, Haugen BR. Ultrasound-based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. J Clin Ultrasound. 2016 Mar-Apr; 44(3):143-51. PMID: 26402153.
      View in: PubMed
    43. McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105. PMID: 26203804.
      View in: PubMed
    44. Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM, Haugen BR. Targeting the NF-?B Pathway as a Combination Therapy for Advanced Thyroid Cancer. PLoS One. 2015; 10(8):e0134901. PMID: 26263379.
      View in: PubMed
    45. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9. PMID: 26171797.
      View in: PubMed
    46. Knight M, Elhelu O, Smith M, Haugen B, Miller A, Raghavan N, Wellman C, Cousin C, Dixon F, Mann V, Rinaldi G, Ittiprasert W, Brindley PJ. Susceptibility of Snails to Infection with Schistosomes is influenced by Temperature and Expression of Heat Shock Proteins. Epidemiology (Sunnyvale). 2015 Jun; 5(2). PMID: 26504668.
      View in: PubMed
    47. Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid. 2015 May; 25(5):563-4. PMID: 25778496.
      View in: PubMed
    48. Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun; 6(2-3):87-99. PMID: 25800363.
      View in: PubMed
    49. Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC, Sams SB, Haugen BR, French JD. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015 Jun; 3(6):620-30. PMID: 25701326.
      View in: PubMed
    50. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb; 100(2):E243-52. PMID: 25427145.
      View in: PubMed
    51. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. J Clin Endocrinol Metab. 2014 Oct; 99(10):3487-8. PMID: 25279569.
      View in: PubMed
    52. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942- 2014. Horm Cancer. 2014 Oct; 5(5):263-4. PMID: 25200857.
      View in: PubMed
    53. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Endocr Rev. 2014 Oct; 35(5):715-6. PMID: 25247379.
      View in: PubMed
    54. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Endocrinology. 2014 Oct; 155(10):3727-8. PMID: 25238132.
      View in: PubMed
    55. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Mol Endocrinol. 2014 Oct; 28(10):1587-8. PMID: 25271789.
      View in: PubMed
    56. Olson AC, Haugen BR, Walter J, Kwak JJ, Bagrosky BM, Koo PJ. SPECT/CT and I131 therapy of brain metastases from follicular variant papillary thyroid carcinoma (FVPTC). J Clin Endocrinol Metab. 2014 Oct; 99(10):3511-2. PMID: 25057877.
      View in: PubMed
    57. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1436-44. PMID: 24758177.
      View in: PubMed
    58. Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Jul; 99(7):E1368-75. PMID: 24712572.
      View in: PubMed
    59. Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014 Mar 19; 13:62. PMID: 24645981.
      View in: PubMed
    60. Koo PJ, Klingensmith WC, Bagrosky BM, Haugen BR. SPECT/CT of metastatic struma ovarii. Clin Nucl Med. 2014 Feb; 39(2):186-7. PMID: 23797234.
      View in: PubMed
    61. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2014 Jan; 99(1):119-25. PMID: 24152684.
      View in: PubMed
    62. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb; 24(2):232-40. PMID: 23721245.
      View in: PubMed
    63. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014 Jan; 24(1):35-42. PMID: 23731273.
      View in: PubMed
    64. Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, Diggans J, Friedman L, Kennedy GC, Kloos RT, Lanman RB, Mandel SJ, Sindy N, Steward DL, Zeiger MA, Haugen BR, Alexander EK. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med. 2013 Sep 03; 159(5):325-32. PMID: 24026318.
      View in: PubMed
    65. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun; 34(3):439-55. PMID: 23575762.
      View in: PubMed
    66. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013 Mar 23; 381(9871):1058-69. PMID: 23668556.
      View in: PubMed
    67. Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE. Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res. 2013 Mar; 55(1-3):22-33. PMID: 22941561.
      View in: PubMed
    68. Haugen BR. Radioiodine remnant ablation: current indications and dosing regimens. Endocr Pract. 2012 Jul-Aug; 18(4):604-10. PMID: 22849876.
      View in: PubMed
    69. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012 Aug 23; 367(8):705-15. PMID: 22731672.
      View in: PubMed
    70. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 01; 18(13):3580-91. PMID: 22586301.
      View in: PubMed
    71. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012 Jun; 97(6):E878-87. PMID: 22496497.
      View in: PubMed
    72. Haugen B, Hennessey JV, Wartofsky L. Radioactive iodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2012 Apr; 97(4):29A-30A. PMID: 22493315.
      View in: PubMed
    73. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Klopper JP, Haugen BR. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab. 2012 Jun; 97(6):E934-43. PMID: 22466343.
      View in: PubMed
    74. Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR. PPAR? Promotes Growth and Invasion of Thyroid Cancer Cells. PPAR Res. 2011; 2011:171765. PMID: 22194735.
      View in: PubMed
    75. Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid. 2011 Sep; 21(9):941-4. PMID: 21877921.
      View in: PubMed
    76. Haugen B, Hennessey JV, Leonard W. Patient Information Page. Medicines for hypothyroidism. J Clin Endocrinol Metab. 2011 Aug; 96(8):1, 2. PMID: 21816791.
      View in: PubMed
    77. Janssen JS, Sharma V, Pugazhenthi U, Sladek C, Wood WM, Haugen BR. A rexinoid antagonist increases the hypothalamic-pituitary-thyroid set point in mice and thyrotrope cells. Mol Cell Endocrinol. 2011 Jun 06; 339(1-2):1-6. PMID: 21458528.
      View in: PubMed
    78. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec; 20(12):1423-4. PMID: 21054207.
      View in: PubMed
    79. Haugen BR, Duncan MW. Applications of proteomics to thyroid neoplasms: are we there yet? Thyroid. 2010 Oct; 20(10):1051-2. PMID: 20883170.
      View in: PubMed
    80. Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 2010 May 21; 9:117. PMID: 20492683.
      View in: PubMed
    81. Hennessey JV, Malabanan AO, Haugen BR, Levy EG. Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the american thyroid association, american association of clinical endocrinologists, and the endocrine society. Endocr Pract. 2010 May-Jun; 16(3):357-70. PMID: 20551006.
      View in: PubMed
    82. Michels A, Haugen B. Malignant struma ovarii. J Clin Endocrinol Metab. 2010 Apr; 95(4):1505. PMID: 20375218.
      View in: PubMed
    83. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010 May; 95(5):2325-33. PMID: 20207826.
      View in: PubMed
    84. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab. 2010 Mar; 95(3):987-93. PMID: 20203334.
      View in: PubMed
    85. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009 Dec; 23(6):793-800. PMID: 19942154.
      View in: PubMed
    86. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov; 19(11):1167-214. PMID: 19860577.
      View in: PubMed
    87. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009 Nov; 94(11):4171-9. PMID: 19850694.
      View in: PubMed
    88. Klopper JP, Sharma V, Bissonnette R, Haugen BR. Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. PPAR Res. 2010; 2010:729876. PMID: 19859558.
      View in: PubMed
    89. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009 Oct; 19(10):1043-8. PMID: 19772419.
      View in: PubMed
    90. Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid. 2009 Aug; 19(8):825-35. PMID: 19500021.
      View in: PubMed
    91. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009 Jun; 94(6):2092-8. PMID: 19318445.
      View in: PubMed
    92. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009 Jun; 94(6):2199-203. PMID: 19293266.
      View in: PubMed
    93. Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer. 2009 Mar 06; 8:16. PMID: 19267912.
      View in: PubMed
    94. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008 Nov; 93(11):4331-41. PMID: 18713817.
      View in: PubMed
    95. Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, Mazzaferri EL, Medeiros-Neto G, Reiners C, Robbins RJ, Robinson BG, Schlumberger M, Yamashita S, Pacini F. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid. 2008 Jul; 18(7):687-94. PMID: 18630995.
      View in: PubMed
    96. Klopper J, Haugen B. Can calcitonin and carcinoembryonic antigen doubling times predict progression of thyroid carcinoma? Nat Clin Pract Endocrinol Metab. 2008 Aug; 4(8):428-9. PMID: 18542112.
      View in: PubMed
    97. Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR, Duncan MW. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res. 2008 Mar 01; 68(5):1572-80. PMID: 18316623.
      View in: PubMed
    98. Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res. 2008 Jan 15; 14(2):589-96. PMID: 18223235.
      View in: PubMed
    99. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec; 16(12):1229-42. PMID: 17199433.
      View in: PubMed
    100. Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007 Jan; 92(1):124-30. PMID: 17062760.
      View in: PubMed
    101. Haugen BR. Does the metabolic activity of metastatic thyroid carcinoma correlate with prognosis? Nat Clin Pract Endocrinol Metab. 2006 Sep; 2(9):488-9. PMID: 16957760.
      View in: PubMed
    102. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006 Aug; 45(8):613-26. PMID: 16788983.
      View in: PubMed
    103. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13; 25(16):2304-17. PMID: 16331265.
      View in: PubMed
    104. H?nscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006 Apr; 47(4):648-54. PMID: 16595499.
      View in: PubMed
    105. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006 Feb; 16(2):109-42. PMID: 16420177.
      View in: PubMed
    106. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar; 91(3):878-84. PMID: 16394083.
      View in: PubMed
    107. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar; 91(3):926-32. PMID: 16384850.
      View in: PubMed
    108. Sharma V, Hays WR, Wood WM, Pugazhenthi U, St Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology. 2006 Mar; 147(3):1438-51. PMID: 16306084.
      View in: PubMed
    109. Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC, Sukumar S, Sidransky D. Tumor-specific changes in mtDNA content in human cancer. Int J Cancer. 2005 Oct 10; 116(6):920-4. PMID: 15856456.
      View in: PubMed
    110. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004 Oct; 122(4):524-31. PMID: 15487449.
      View in: PubMed
    111. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep; 4(3):175-80. PMID: 15379720.
      View in: PubMed
    112. Woodmansee WW, Haugen BR. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf). 2004 Aug; 61(2):163-73. PMID: 15272910.
      View in: PubMed
    113. Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab. 2004 Aug; 89(8):3665-7. PMID: 15292284.
      View in: PubMed
    114. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther. 2004 Aug; 3(8):1011-20. PMID: 15299084.
      View in: PubMed
    115. Haugen BR, Jensen DR, Sharma V, Pulawa LK, Hays WR, Krezel W, Chambon P, Eckel RH. Retinoid X receptor gamma-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology. 2004 Aug; 145(8):3679-85. PMID: 15087432.
      View in: PubMed
    116. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab. 2004 Jan; 89(1):272-80. PMID: 14715861.
      View in: PubMed
    117. McDermott MT, Woodmansee WW, Haugen BR, Smart A, Ridgway EC. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid. 2003 Dec; 13(12):1133-9. PMID: 14751034.
      View in: PubMed
    118. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Apr; 88(4):1433-41. PMID: 12679418.
      View in: PubMed
    119. McDermott MT, Haugen BR, Black JN, Wood WM, Gordon DF, Ridgway EC. Congenital isolated central hypothyroidism caused by a "hot spot" mutation in the thyrotropin-beta gene. Thyroid. 2002 Dec; 12(12):1141-6. PMID: 12593729.
      View in: PubMed
    120. McDermott NB, Gordon DF, Kramer CA, Liu Q, Linney E, Wood WM, Haugen BR. Isolation and functional analysis of the mouse RXRgamma1 gene promoter in anterior pituitary cells. J Biol Chem. 2002 Sep 27; 277(39):36839-44. PMID: 12114515.
      View in: PubMed
    121. Sugawara M, Matsuzuka F, Fukata S, Kuma K, Moatamed F, Haugen BR. Excessive survivin expression in thyroid lymphomas. Hum Pathol. 2002 May; 33(5):524-7. PMID: 12094378.
      View in: PubMed
    122. Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf). 2002 Mar; 56(3):281-90. PMID: 11940037.
      View in: PubMed
    123. Lehner R, Enomoto T, McGregor JA, Shroyer L, Haugen BR, Pugazhenthi U, Shroyer KR. Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma. Acta Obstet Gynecol Scand. 2002 Feb; 81(2):162-7. PMID: 11942908.
      View in: PubMed
    124. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, Shroyer KR. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol. 2002 Jan; 84(1):120-5. PMID: 11748987.
      View in: PubMed
    125. Haugen BR, Lin EC. Isotope imaging for metastatic thyroid cancer. Endocrinol Metab Clin North Am. 2001 Jun; 30(2):469-92. PMID: 11444171.
      View in: PubMed
    126. Haugen BR. The risks and benefits of radioiodine therapy for thyroid carcinoma remain somewhat undifferentiated. Thyroid. 2000 Nov; 10(11):971-3. PMID: 11128724.
      View in: PubMed
    127. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, Haugen BR. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J Clin Invest. 2000 Jul; 106(1):73-9. PMID: 10880050.
      View in: PubMed
    128. Haugen BR. Initial treatment of differentiated thyroid carcinoma. Rev Endocr Metab Disord. 2000 Apr; 1(3):139-45. PMID: 11704999.
      View in: PubMed
    129. McDermott MT, Haugen BR, Gordon DF, Wood WM, Brown NS, Bauer CA, Garrity MJ, Kleinschmidt-DeMasters BK, Lillehei KO, Samuels MH, Bright TM, Ridgway EC. Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors. Pituitary. 1999 Nov; 2(3):217-24. PMID: 11081157.
      View in: PubMed
    130. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999 Nov; 84(11):3877-85. PMID: 10566623.
      View in: PubMed
    131. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999 Apr 08; 340(14):1075-9. PMID: 10194237.
      View in: PubMed
    132. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999 Jan-Feb; 16(1):34-41. PMID: 9890738.
      View in: PubMed
    133. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-H?rthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998 Oct 15; 129(8):622-7. PMID: 9786809.
      View in: PubMed
    134. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998 Sep 01; 83(5):1012-21. PMID: 9731906.
      View in: PubMed
    135. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998 Sep; 8(9):737-44. PMID: 9777742.
      View in: PubMed
    136. Yost TJ, Jensen DR, Haugen BR, Eckel RH. Effect of dietary macronutrient composition on tissue-specific lipoprotein lipase activity and insulin action in normal-weight subjects. Am J Clin Nutr. 1998 Aug; 68(2):296-302. PMID: 9701186.
      View in: PubMed
    137. Gordon DF, Lewis SR, Haugen BR, James RA, McDermott MT, Wood WM, Ridgway EC. Pit-1 and GATA-2 interact and functionally cooperate to activate the thyrotropin beta-subunit promoter. J Biol Chem. 1997 Sep 26; 272(39):24339-47. PMID: 9305891.
      View in: PubMed
    138. Haugen BR, Nawaz S, Markham N, Hashizumi T, Shroyer AL, Werness B, Shroyer KR. Telomerase activity in benign and malignant thyroid tumors. Thyroid. 1997 Jun; 7(3):337-42. PMID: 9226200.
      View in: PubMed
    139. Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC. The thyrotrope-restricted isoform of the retinoid-X receptor-gamma1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity. Mol Endocrinol. 1997 Apr; 11(4):481-9. PMID: 9092800.
      View in: PubMed
    140. Wood WM, Dowding JM, Bright TM, McDermott MT, Haugen BR, Gordon DF, Ridgway EC. Thyroid hormone receptor beta2 promoter activity in pituitary cells is regulated by Pit-1. J Biol Chem. 1996 Sep 27; 271(39):24213-20. PMID: 8798664.
      View in: PubMed
    141. Haugen BR, McDermott MT, Gordon DF, Rupp CL, Wood WM, Ridgway EC. Determinants of thyrotrope-specific thyrotropin beta promoter activation. Cooperation of Pit-1 with another factor. J Biol Chem. 1996 Jan 05; 271(1):385-9. PMID: 8550592.
      View in: PubMed
    142. Ng L, Forrest D, Haugen BR, Wood WM, Curran T. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone. Mol Endocrinol. 1995 Sep; 9(9):1202-13. PMID: 7491112.
      View in: PubMed
    143. Lossie AC, Haugen BR, Wood WM, Camper SA, Gordon DF. Chromosomal localization of the large subunit of mouse replication factor C in the mouse and human. Mamm Genome. 1995 Jan; 6(1):58-9. PMID: 7719032.
      View in: PubMed
    144. Wood WM, Dowding JM, Haugen BR, Bright TM, Gordon DF, Ridgway EC. Structural and functional characterization of the genomic locus encoding the murine beta 2 thyroid hormone receptor. Mol Endocrinol. 1994 Dec; 8(12):1605-17. PMID: 7708051.
      View in: PubMed
    145. Haugen BR, Gordon DF, Nelson AR, Wood WM, Ridgway EC. The combination of Pit-1 and Pit-1T have a synergistic stimulatory effect on the thyrotropin beta-subunit promoter but not the growth hormone or prolactin promoters. Mol Endocrinol. 1994 Nov; 8(11):1574-82. PMID: 7877626.
      View in: PubMed
    146. Haugen BR, Nawaz S, Cohn A, Shroyer K, Bunn PA, Liechty DR, Ridgway EC. Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid. 1994; 4(3):297-300. PMID: 7833666.
      View in: PubMed
    147. Haugen BR, Wood WM, Gordon DF, Ridgway EC. A thyrotrope-specific variant of Pit-1 transactivates the thyrotropin beta promoter. J Biol Chem. 1993 Oct 05; 268(28):20818-24. PMID: 8407911.
      View in: PubMed
    148. Gordon DF, Haugen BR, Sarapura VD, Nelson AR, Wood WM, Ridgway EC. Analysis of Pit-1 in regulating mouse TSH beta promoter activity in thyrotropes. Mol Cell Endocrinol. 1993 Oct; 96(1-2):75-84. PMID: 8276142.
      View in: PubMed
    Haugen's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (494) concept(s)
    _
    Co-Authors Expand Description
    See all (37) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)